Canavan Disease - Pipeline Review, H2 Pharmaceutical 2016

Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides
an overview of the Canavan Disease (Central Nervous System) pipeline
landscape.
Canavan
disease is a gene-linked neurological disorder in which the brain
degenerates into spongy tissue riddled with microscopic fluid-filled
spaces. Cause includes a mutation in the gene which directs the
production of the enzyme aspartoacylase (ASPA) allows the buildup of
N-acetylaspartic acid (NAA) in the brain. The buildup of NAA causes
damage to myelin. Symptoms include lack of motor development, feeding
difficulties, abnormal muscle tone, and an abnormally large, poorly
controlled head, paralysis, blindness, or hearing loss.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Canavan Disease - Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Canavan Disease
(Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Canavan Disease (Central Nervous System) pipeline guide also reviews
of key players involved in therapeutic development for Canavan
Disease and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase II and
Preclinical stages are 1 and 2 respectively. Similarly, the
Universities portfolio in Preclinical stages comprises 2 molecules,
respectively.Canavan Disease.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Canavan Disease (Central Nervous System).
-
The pipeline guide reviews pipeline therapeutics for Canavan Disease
(Central Nervous System) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Canavan Disease
(Central Nervous System) therapeutics and enlists all their major and
minor projects.
-
The pipeline guide evaluates Canavan Disease (Central Nervous System)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Canavan Disease (Central Nervous System).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Canavan Disease (Central Nervous System) pipeline depth and focus of
Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Comments
Post a Comment